The SAN drug Multaq, used by patients with atrial flutter and atrial fibrillation, or irregular heart rhythms to prevent strokes, has been reported to have caused liver damage in at least two female patients who were approximately
Multaq was approved in July 2009 by the FDA, and half a million prescriptions have been written for the drug ever since.
Sanofi offices in Bridgewater, N.J.
The U.S. Food and Drug Administration has recently released a warning to doctors and patients that Sanofi-Aventis' (SAN) heart drug has been linked to liver damage in several patients.
